CHALLENGE
A leading global pharmaceutical company aimed to launch a key oncology asset in the U.S. through a strategic licensing agreement. With an aggressive timeline of less than 12 months, the company needed seamless coordination across multiple functions, including Regulatory & Labeling, Manufacturing, Market Analytics, Access & Reimbursement, and Medical Affairs. Ensuring alignment among all stakeholders while maintaining execution excellence was critical to success.
SOLUTION
CMK Select embedded a Launch Planning Leader to drive execution through a structured and pragmatic approach. A comprehensive Launch Readiness Review (LRR) framework was implemented across 20+ launch disciplines, ensuring alignment and accountability. A transparent project management process provided clear visibility into milestones, dependencies, and escalation paths. Weekly launch team meetings facilitated progress tracking and rapid issue resolution. Additionally, a Launch Action Plan was developed to define critical tasks and timing for each workstream at FDA approval.
-
100%U.S. launch readiness in under 12 months
-
20+launch disciplines applied across LRR framework
-
25%reduction in admin burden via standardized planning
IMPACT & VALUE REALIZED
The company achieved 100% U.S. launch readiness within the aggressive timeline, meeting all critical milestones without delays. Standardized launch planning processes improved cross-functional coordination and reduced administrative burden by 25%, while proactive issue resolution accelerated decision-making. Through expert launch project leadership and strategic oversight, CMK Select enabled the client to navigate complex launch requirements and position the oncology asset for commercial success.